• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吸烟、肥胖和糖尿病对接受辅助化疗的 III 期结肠癌患者无复发生存和总生存的影响。

The effect of smoking, obesity and diabetes on recurrence-free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy.

机构信息

Department of Surgery, Footscray Hospital, Footscray, Victoria, Australia.

Melbourne Medical School - Western Health Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, St Albans, Victoria, Australia.

出版信息

Cancer Rep (Hoboken). 2021 Jun;4(3):e1346. doi: 10.1002/cnr2.1346. Epub 2021 Feb 7.

DOI:10.1002/cnr2.1346
PMID:33554476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8222556/
Abstract

BACKGROUND

The association between smoking, diabetes and obesity and oncological outcomes in patients with stage III colon cancer treated with surgery and adjuvant chemotherapy is unclear.

AIM

To evaluate whether smoking, obesity and diabetes are associated with the disease-free survival and overall survival rates of patients with stage III colon cancer who have received adjuvant chemotherapy.

METHODS

Patients were selected from the prospectively maintained Australian Cancer Outcomes and Research Database (ACCORD). All stage III colon cancer patients who received adjuvant chemotherapy between January 2003 to December 2015 were retrospectively analyzed. The three primary exposures of interest were smoking status, body mass index (BMI) and diabetic (DM) status. The primary outcomes of interest were disease-free survival (DFS) and overall survival (OS).

RESULTS

A total of 785 patients between 2003 and 2015 were included for analysis. Using Kaplan-Meier survivorship curves, there was no association between OS and smoking (P = .71), BMI (P = .3) or DM (P = .72). Similarly, DFS did not reveal an association with smoking (P = .34), BMI (P = .2) and DM (P = .34). Controlling for other covariates the results did not reach statistical significance in adjusted multiple regression models.

CONCLUSION

Smoking, obesity and DM were not shown to influence DFS or OS for patients with stage III colon cancer who have received adjuvant chemotherapy.

摘要

背景

吸烟、糖尿病和肥胖与接受手术和辅助化疗的 III 期结肠癌患者的肿瘤学结局之间的关系尚不清楚。

目的

评估吸烟、肥胖和糖尿病是否与接受辅助化疗的 III 期结肠癌患者的无病生存率和总生存率相关。

方法

患者从前瞻性维护的澳大利亚癌症结局和研究数据库(ACCORD)中选择。回顾性分析了 2003 年 1 月至 2015 年 12 月期间接受辅助化疗的所有 III 期结肠癌患者。三个主要暴露因素为吸烟状况、体重指数(BMI)和糖尿病(DM)状况。主要关注的结果是无病生存率(DFS)和总生存率(OS)。

结果

2003 年至 2015 年期间共纳入 785 例患者进行分析。使用 Kaplan-Meier 生存曲线,OS 与吸烟(P=0.71)、BMI(P=0.3)或 DM(P=0.72)无关。同样,DFS 与吸烟(P=0.34)、BMI(P=0.2)和 DM(P=0.34)也没有关联。在调整后的多变量回归模型中,控制其他协变量后,结果没有达到统计学意义。

结论

对于接受辅助化疗的 III 期结肠癌患者,吸烟、肥胖和 DM 并未显示影响 DFS 或 OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ce/8222556/6a44f02af0c1/CNR2-4-e1346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ce/8222556/2d25dae5e187/CNR2-4-e1346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ce/8222556/6a44f02af0c1/CNR2-4-e1346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ce/8222556/2d25dae5e187/CNR2-4-e1346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ce/8222556/6a44f02af0c1/CNR2-4-e1346-g002.jpg

相似文献

1
The effect of smoking, obesity and diabetes on recurrence-free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy.吸烟、肥胖和糖尿病对接受辅助化疗的 III 期结肠癌患者无复发生存和总生存的影响。
Cancer Rep (Hoboken). 2021 Jun;4(3):e1346. doi: 10.1002/cnr2.1346. Epub 2021 Feb 7.
2
Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy.肥胖及其对接受辅助化疗的 III 期结肠癌患者结局的影响。
Clin Colorectal Cancer. 2020 Sep;19(3):209-218. doi: 10.1016/j.clcc.2020.02.010. Epub 2020 Feb 26.
3
Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.关于IIIA期结肠癌辅助化疗必要性的争议问题。
Clin Colorectal Cancer. 2020 Dec;19(4):e157-e163. doi: 10.1016/j.clcc.2020.03.001. Epub 2020 Mar 19.
4
Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.肥胖 III 期结肠癌患者化疗剂量减少的临床后果:来自 PETACC 3 研究的回顾性分析。
Eur J Cancer. 2018 Aug;99:49-57. doi: 10.1016/j.ejca.2018.05.004. Epub 2018 Jun 15.
5
Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials.真实世界中 II 期和 III 期结肠癌患者接受辅助化疗试验的资格。
Clin Colorectal Cancer. 2020 Dec;19(4):e226-e234. doi: 10.1016/j.clcc.2020.05.005. Epub 2020 May 26.
6
Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.替加氟/尿嘧啶辅助化疗超过1年可提高低危II期结肠癌的无病生存率。
J Chin Med Assoc. 2016 Sep;79(9):477-88. doi: 10.1016/j.jcma.2016.04.001. Epub 2016 Jun 18.
7
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).接受辅助化疗的Ⅲ期结肠癌切除患者使用二甲双胍与复发及生存的关系:来自中北部癌症治疗组N0147(联盟)的结果
Oncologist. 2016 Dec;21(12):1509-1521. doi: 10.1634/theoncologist.2016-0153. Epub 2016 Nov 23.
8
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.JOIN 试验:接受改良 FOLFOX6 辅助治疗 II/III 期结肠癌患者在 3 年随访期间外周感觉神经病变的治疗结果和恢复状况。
Cancer Chemother Pharmacol. 2019 Dec;84(6):1269-1277. doi: 10.1007/s00280-019-03957-5. Epub 2019 Sep 23.
9
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.在临床环境中,III期结肠癌手术时不进行口服化疗的肿瘤学预后较差。
World J Surg Oncol. 2014 May 10;12:145. doi: 10.1186/1477-7819-12-145.
10
S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.S-1 和奥沙利铂对比替加氟-尿嘧啶/亚叶酸钙作为 III 期高危结肠癌患者术后辅助化疗(ACTS-CC 02):一项随机、开放标签、多中心、III 期优效性试验。
Clin Colorectal Cancer. 2020 Mar;19(1):22-31.e6. doi: 10.1016/j.clcc.2019.10.002. Epub 2019 Oct 18.

引用本文的文献

1
Alcohol Consumption and Smoking History at the Time of Diagnosis and the Risk of Colorectal Cancer Recurrence and Mortality: Results from the ColoCare Study.诊断时的饮酒和吸烟史与结直肠癌复发及死亡风险:ColoCare研究结果
Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):59-66. doi: 10.1158/1055-9965.EPI-24-0834.
2
Oral cavity and oropharyngeal carcinoma disparities in age and survival in Indigenous and non-Indigenous populations of Queensland.昆士兰州土著和非土著人群口腔和口咽癌的年龄和生存差异。
BMC Cancer. 2023 Jun 3;23(1):503. doi: 10.1186/s12885-023-11002-1.
3
WDR74 promotes proliferation and metastasis in colorectal cancer cells through regulating the Wnt/β-catenin signaling pathway.

本文引用的文献

1
Risk of colon cancer recurrence in relation to diabetes.结肠癌复发风险与糖尿病的关系。
Cancer Causes Control. 2018 Nov;29(11):1093-1103. doi: 10.1007/s10552-018-1083-3. Epub 2018 Sep 22.
2
An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients.结直肠癌患者 25 年发病、治疗和转归概述。
Int J Cancer. 2018 Dec 1;143(11):2758-2766. doi: 10.1002/ijc.31785. Epub 2018 Sep 29.
3
Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium.
WDR74通过调节Wnt/β-连环蛋白信号通路促进结肠癌细胞的增殖和转移。
Open Life Sci. 2021 Sep 6;16(1):920-929. doi: 10.1515/biol-2021-0096. eCollection 2021.
诊断前吸烟和戒烟对结直肠癌预后的影响:来自 CHANCES 联盟队列的个体患者数据的荟萃分析。
Ann Oncol. 2018 Feb 1;29(2):472-483. doi: 10.1093/annonc/mdx761.
4
Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies.腹部肥胖与结直肠癌风险:前瞻性研究的系统评价和荟萃分析。
Biosci Rep. 2017 Dec 12;37(6). doi: 10.1042/BSR20170945. Print 2017 Dec 22.
5
Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype.酒精摄入、吸烟、身体活动及肥胖与结直肠癌诊断后按分期、解剖部位和肿瘤分子亚型划分的生存率之间的关联。
Int J Cancer. 2018 Jan 15;142(2):238-250. doi: 10.1002/ijc.31049. Epub 2017 Oct 4.
6
Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies.高血糖对化疗疗效的影响——临床前研究的系统评价
Crit Rev Oncol Hematol. 2017 May;113:235-241. doi: 10.1016/j.critrevonc.2017.03.007. Epub 2017 Mar 10.
7
A retrospective cohort study of the influence of lifestyle factors on the survival of patients undergoing surgery for colorectal cancer.一项关于生活方式因素对接受结直肠癌手术患者生存影响的回顾性队列研究。
Colorectal Dis. 2017 Jun;19(6):544-550. doi: 10.1111/codi.13594.
8
Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre.在一家大型癌症中心接受评估的结直肠癌患者中,诊断前的重度肥胖会限制其生存期。
Br J Cancer. 2016 Jan 12;114(1):103-9. doi: 10.1038/bjc.2015.424. Epub 2015 Dec 17.
9
Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy.内脏脂肪过多是接受辅助化疗的结直肠癌患者预后不良的一个危险因素。
J Gastrointest Cancer. 2015 Sep;46(3):243-50. doi: 10.1007/s12029-015-9709-0.
10
Diabetes mellitus and colorectal cancer prognosis: a meta-analysis.糖尿病与结直肠癌预后的关系:一项荟萃分析。
Dis Colon Rectum. 2013 Nov;56(11):1304-19. doi: 10.1097/DCR.0b013e3182a479f9.